RecruitingNCT07235527
Real-Life Clinical Outcomes of Aflibercept Biosimilar MY-1701P in the Treatment of Exudative Age-Related Macular Degeneration
Real-World Outcomes of Aflibercept Biosimilar MY-1701P Treatment in Exudative Age-Related Macular Degeneration
Sponsor
Saglik Bilimleri Universitesi
Enrollment
54 participants
Start Date
Nov 20, 2025
Study Type
OBSERVATIONAL
Conditions
Summary
In this study, patients receiving Eylea treatment will be treated with Yesafili, a biosimilar molecule, and routine examination results will be noted.
Eligibility
Min Age: 45 YearsMax Age: 90 Years
Inclusion Criteria3
- Patients aged between 45 and 90 years with active neovascular age-related macular degeneration (nAMD)
- who show signs of disease activity on routine ophthalmologic examination and optical coherence tomography (OCT)
- for whom intravitreal injection has already been clinically indicated
Exclusion Criteria7
- Patients younger than 45 years or older than 90 years
- History of stroke, cerebrovascular event, myocardial infarction, or coronary stent placement within the last six months
- Presence of uveitis
- Media opacity preventing adequate retinal imaging (e.g., corneal opacity, mature cataract)
- Coexistence of other retinal vascular diseases (e.g., branch retinal vein occlusion, diabetic macular edema)
- Presence of hereditary retinal dystrophies
- Presence of optic atrophy
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGAflibercept biosimilar (MY-1701P)
Patients receiving the aflibercept biosimilar MY-1701P (marketed as Yesafili®) as part of routine clinical care.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07235527
Related Trials
Phase 1 Study of C.001 in Retinal Degeneration
NCT075942361 location
Village-Integrated Eye Worker Trial II
NCT037528401 location
National Eye Institute Biorepository for Retinal Diseases
NCT014966251 location
Safety of BBC1501 Intravitreal Injection in Patients With Neovascular Age-Related Macular Degeneration (nAMD)
NCT058037852 locations
The Role of Occupational Therapy for Improving Medication Management for Persons With AMD, DR and Glaucoma
NCT065934051 location